NeOnc rises as experimental brain cancer therapy meets main study goal

Neonc Technologies Holdings

12/08/2026 13:15

** Shares of NeOnc Technologies NTHI.O rise 12.4% to $4.89 premarket
** The clinical-stage brain cancer drug developer says experimental brain cancer therapy NEO100 met the main goal in a mid-stage study in recurrent high-grade glioma, an aggressive brain tumor that has returned after treatment
** Co says six-month progression-free survival was 48.9%, above the study's pre-specified 20% benchmark for standard care
** Company reported median overall survival of 26.1 months, with 86.7% of patients alive at six months
** Co says no major toxicities were reported and side effects were mainly low-grade
** Plans a Type B meeting with the FDA to discuss a potential registration pathway in a setting with no approved targeted therapies
** As of last close, stock down ~47% YTD
  
 

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))